Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.

• DOI: 10.1200/jco.2011.29.15_suppl.2
• Publication Date: 2017-02-23T18:58:03Z
• Authors: R. L. Ladenstein; U. Poetschger; R. Luksch; P. Brock; V. Castel; I. Yaniv; V. Papadakis; G. Laureys; J. Malis; W. Balwierz; E. Ruud; P. Kogner; H. Schroeder; A. Forjaz De Lacerda; M. Beck Popovic; P. Bician; M. Garami; T. Trahair; A. D. Pearson; D. Valteau Couanet
• Keywords: Melphalan; Clinical Oncology

2 The full, final text of this abstract will be available in Part II the 2011 Annual Meeting Proceedings, distributed onsite at on June 4, 2011, and as a supplement to 20, issue Journal Clinical Oncology.